Achieve Life Sciences (ACHV) Stock Forecast, Price Target & Predictions

OverviewOwnership Financials Chart Transcripts

ACHV Stock Forecast

Achieve Life Sciences stock forecast is as follows: an average price target of $4.75 (represents a 28.73% upside from ACHV’s last price of $3.69) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

ACHV Price Target

The average price target for Achieve Life Sciences (ACHV) is $4.75 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $5.50 to $4.00. This represents a potential 28.73% upside from ACHV's last price of $3.69.

ACHV Analyst Ratings

Buy

According to 3 Wall Street analysts, Achieve Life Sciences's rating consensus is 'Buy'. The analyst rating breakdown for ACHV stock is 1 'Strong Buy' (33.33%), 2 'Buy' (66.67%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Achieve Life Sciences Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
May 13, 2024	Francois Brisebois	Oppenheimer	$5.50	$2.42	127.27%	49.05%
Nov 16, 2022		Maxim Group	$4.00	$1.13	253.98%	8.40%

The latest Achieve Life Sciences stock forecast, released on May 13, 2024 by Francois Brisebois from Oppenheimer, set a price target of $5.50, which represents a 127.27% increase from the stock price at the time of the forecast ($2.42), and a 49.05% increase from ACHV last price ($3.69).

Achieve Life Sciences Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$5.50
Last Closing Price	$3.69	$3.69	$3.69
Upside/Downside	-100.00%	-100.00%	49.05%

In the current month, the average price target of Achieve Life Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Achieve Life Sciences's last price of $3.69. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 26, 2024	Raymond James		Strong Buy	Initialise
May 13, 2024	Oppenheimer	Outperform	Outperform	Hold
Dec 12, 2023	Oppenheimer	Outperform	Outperform	Hold
Nov 16, 2022	Maxim Group	Buy	Buy	Hold

Achieve Life Sciences's last stock rating was published by Raymond James on Sep 26, 2024. The company Initialise its ACHV rating from "null" to "Strong Buy".

Achieve Life Sciences Financial Forecast

Achieve Life Sciences Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 22	Sep 22	Jun 22	Dec 21	Mar 16	Mar 15	Mar 14	Mar 13	Mar 12	Mar 11	Mar 10	Mar 07	Mar 06	Mar 04	Mar 03	Mar 02	Mar 99	Jun 98	Mar 97	Mar 96	Dec 95
Revenue	-	-	-	-	-	-	-	-	-	-	-	$2.94M	$1.37M	$11.73M	$5.08M	$1.32M	$1.20M	$4.70M	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	$125.00K	$62.50K	$62.50K	$50.00K	$2.86M	$2.33M	$9.84M	$7.79M	$1.45M	$1.84M	$4.78M	$12.91M	$6.67M	$39.38K	$42.35K	$30.00K	$2.22M	$885.12K	$3.97M	$371.24K	$441.77K
High Forecast	-	-	-	-	-	-	-	$125.00K	$62.50K	$62.50K	$50.00K	$3.43M	$2.79M	$11.81M	$9.34M	$1.74M	$2.21M	$5.74M	$15.49M	$8.00M	$47.25K	$50.82K	$36.00K	$2.66M	$1.06M	$4.76M	$445.49K	$530.12K
Low Forecast	-	-	-	-	-	-	-	$125.00K	$62.50K	$62.50K	$50.00K	$2.29M	$1.86M	$7.87M	$6.23M	$1.16M	$1.47M	$3.83M	$10.33M	$5.34M	$31.50K	$33.88K	$24.00K	$1.77M	$708.10K	$3.17M	$296.99K	$353.41K
# Analysts	-	-	-	-	-	-	-	1	5	5	6	12	10	16	17	16	16	14	11	12	16	10	12	7	8	16	9	10
Surprise %	-	-	-	-	-	-	-	-	-	-	-	1.03%	0.59%	1.19%	0.65%	0.91%	0.65%	0.98%	-	-	-	-	-	-	-	-	-	-

Achieve Life Sciences's average Quarter revenue forecast for Dec 21 based on 6 analysts is $50.00K, with a low forecast of $50.00K, and a high forecast of $50.00K. ACHV's average Quarter revenue forecast represents a -98.30% decrease compared to the company's last Quarter revenue of $2.94M (Mar 16).

Achieve Life Sciences EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 22	Sep 22	Jun 22	Dec 21	Mar 16	Mar 15	Mar 14	Mar 13	Mar 12	Mar 11	Mar 10	Mar 07	Mar 06	Mar 04	Mar 03	Mar 02	Mar 99	Jun 98	Mar 97	Mar 96	Dec 95
# Analysts	-	-	-	-	-	-	-	1	5	5	6	12	10	16	17	16	16	14	11	12	16	10	12	7	8	16	9	10
EBITDA	-	-	-	-	-	-	-	$-10.86M	$-12.54M	$-10.01M	$-7.09M	$-3.65M	$-4.47M	$-8.58M	$-6.65M	$-6.84M	$-3.03M	$-3.03M	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	$-3.55M	$-5.68M	$-6.93M	$-8.97M	$-7.44M	$-4.08M	$-3.08M	$-4.75M	$-7.20M	$-3.83M	$-2.81M	$-2.25M	$-1.38M	$-3.41M	$1.34M	$-4.15M	$-3.20M
High Forecast	-	-	-	-	-	-	-	-	-	-	-	$-2.84M	$-4.54M	$-5.55M	$-7.17M	$-5.95M	$-3.27M	$-2.47M	$-3.80M	$-5.76M	$-3.07M	$-2.25M	$-1.80M	$-1.11M	$-2.73M	$1.60M	$-3.32M	$-2.56M
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	$-4.25M	$-6.82M	$-8.32M	$-10.76M	$-8.92M	$-4.90M	$-3.70M	$-5.70M	$-8.64M	$-4.60M	$-3.37M	$-2.70M	$-1.66M	$-4.10M	$1.07M	$-4.98M	$-3.84M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	1.03%	0.79%	1.24%	0.74%	0.92%	0.74%	0.98%	-	-	-	-	-	-	-	-	-	-

undefined analysts predict ACHV's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Achieve Life Sciences's previous annual EBITDA (undefined) of $NaN.

Achieve Life Sciences Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 22	Sep 22	Jun 22	Dec 21	Mar 16	Mar 15	Mar 14	Mar 13	Mar 12	Mar 11	Mar 10	Mar 07	Mar 06	Mar 04	Mar 03	Mar 02	Mar 99	Jun 98	Mar 97	Mar 96	Dec 95
# Analysts	-	-	-	-	-	-	-	1	5	5	6	12	10	16	17	16	16	14	11	12	16	10	12	7	8	16	9	10
Net Income	-	-	-	-	-	-	-	$-10.99M	$-13.56M	$-10.87M	$-7.19M	$-2.98M	$-4.04M	$-9.34M	$-5.12M	$-8.22M	$-865.00K	$-3.06M	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$-10.88M	$-10.22M	$-10.22M	$-12.20M	$-11.72M	$-9.33M	$-8.19M	$-32.52M	$-38.67M	$-27.85M	$-23.63M	$-3.60M	$-5.74M	$-6.98M	$-9.02M	$-7.46M	$-4.11M	$-3.10M	$-4.67M	$-7.40M	$-3.90M	$-2.94M	$-2.41M	$-1.80M	$-3.92M	$971.15K	$-4.34M	$-3.42M
High Forecast	$-10.88M	$-10.22M	$-10.22M	$-10.55M	$-7.82M	$-9.33M	$-8.19M	$-32.52M	$-38.67M	$-27.85M	$-23.63M	$-2.88M	$-4.59M	$-5.58M	$-7.22M	$-5.97M	$-3.29M	$-2.48M	$-3.74M	$-5.92M	$-3.12M	$-2.35M	$-1.93M	$-1.44M	$-3.14M	$1.17M	$-3.47M	$-2.74M
Low Forecast	$-10.88M	$-10.22M	$-10.22M	$-13.84M	$-15.24M	$-9.33M	$-8.19M	$-32.52M	$-38.67M	$-27.85M	$-23.63M	$-4.32M	$-6.89M	$-8.37M	$-10.83M	$-8.95M	$-4.93M	$-3.72M	$-5.60M	$-8.88M	$-4.68M	$-3.53M	$-2.89M	$-2.16M	$-4.70M	$776.92K	$-5.20M	$-4.11M
Surprise %	-	-	-	-	-	-	-	0.34%	0.35%	0.39%	0.30%	0.83%	0.70%	1.34%	0.57%	1.10%	0.21%	0.99%	-	-	-	-	-	-	-	-	-	-

Achieve Life Sciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ACHV's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Achieve Life Sciences SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 22	Sep 22	Jun 22	Dec 21	Mar 16	Mar 15	Mar 14	Mar 13	Mar 12	Mar 11	Mar 10	Mar 07	Mar 06	Mar 04	Mar 03	Mar 02	Mar 99	Jun 98	Mar 97	Mar 96	Dec 95
# Analysts	-	-	-	-	-	-	-	1	5	5	6	12	10	16	17	16	16	14	11	12	16	10	12	7	8	16	9	10
SG&A	-	-	-	-	-	-	-	$2.25M	$2.77M	$2.87M	$2.61M	$2.30M	$2.70M	$2.76M	$2.50M	$1.74M	$1.57M	$1.35M	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	$2.23M	-	$2.23M	$3.37M	-	-	$1.37M	$2.86M	$2.46M	-	-	-	-	-	$856.90K	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-	$2.68M	-	$2.67M	$4.04M	-	-	$1.65M	$3.43M	$2.96M	-	-	-	-	-	$1.03M	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	$1.79M	-	$1.78M	$2.70M	-	-	$1.10M	$2.29M	$1.97M	-	-	-	-	-	$685.52K	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	1.03%	-	1.24%	0.74%	-	-	0.98%	-	-	-	-	-	-	-	-	-	-

Achieve Life Sciences's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to ACHV last annual SG&A of $2.25M (Dec 22).

Achieve Life Sciences EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 22	Sep 22	Jun 22	Dec 21	Mar 16	Mar 15	Mar 14	Mar 13	Mar 12	Mar 11	Mar 10	Mar 07	Mar 06	Mar 04	Mar 03	Mar 02	Mar 99	Jun 98	Mar 97	Mar 96	Dec 95
# Analysts	-	-	-	-	-	-	-	1	5	5	6	12	10	16	17	16	16	14	11	12	16	10	12	7	8	16	9	10
EPS	-	-	-	-	-	-	-	$-0.81	$-1.40	$-1.13	$-0.76	$-219.94	$-392.02	$-1.40K	$-767.67	$-1.77K	$-195.92	$-1.06K	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$-0.32	$-0.30	$-0.30	$-0.35	$-0.34	$-0.27	$-0.24	$-0.95	$-1.13	$-0.81	$-0.69	$-12.46	$-0.43	$-44.00	$-104.50	$-87.78	$-70.62	$-54.64	$-36.63	$-42.90	$-26.40	$-34.10	$-19.80	$-33.00	$-84.15	$4.98	$-27.40	$-54.26
High Forecast	$-0.32	$-0.30	$-0.30	$-0.31	$-0.23	$-0.27	$-0.24	$-0.95	$-1.13	$-0.81	$-0.69	$-9.97	$-0.35	$-35.20	$-83.60	$-70.22	$-56.50	$-43.71	$-29.30	$-34.32	$-21.12	$-27.28	$-15.84	$-26.40	$-67.32	$5.97	$-21.92	$-43.41
Low Forecast	$-0.32	$-0.30	$-0.30	$-0.40	$-0.44	$-0.27	$-0.24	$-0.95	$-1.13	$-0.81	$-0.69	$-14.95	$-0.52	$-52.80	$-125.40	$-105.34	$-84.74	$-65.57	$-43.96	$-51.48	$-31.68	$-40.92	$-23.76	$-39.60	$-100.98	$3.98	$-32.88	$-65.11
Surprise %	-	-	-	-	-	-	-	0.86%	1.24%	1.39%	1.10%	17.65%	911.67%	31.74%	7.35%	20.12%	2.77%	19.45%	-	-	-	-	-	-	-	-	-	-

According to undefined Wall Street analysts, Achieve Life Sciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ACHV previous annual EPS of $NaN (undefined).

Achieve Life Sciences Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HEPA	Hepion Pharmaceuticals	$0.52	$70.00	13361.54%	Buy
SPRO	Spero Therapeutics	$1.04	$10.00	861.54%	Buy
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
XFOR	X4 Pharmaceuticals	$0.74	$3.67	395.95%	Buy
CNSP	CNS Pharmaceuticals	$0.11	$0.50	354.55%
ITOS	iTeos Therapeutics	$7.69	$33.50	335.63%	Buy
TCRX	TScan Therapeutics	$2.97	$12.00	304.04%	Buy
ABOS	Acumen Pharmaceuticals	$1.96	$7.00	257.14%	Buy
CHRS	Coherus BioSciences	$1.71	$6.00	250.88%	Hold
NXTC	NextCure	$0.90	$3.00	233.33%	Buy
CTMX	CytomX Therapeutics	$1.13	$3.47	207.08%	Buy
IMMX	Immix Biopharma	$2.29	$7.00	205.68%	Buy
ASMB	Assembly Biosciences	$14.28	$35.50	148.60%	Buy
APLS	Apellis Pharmaceuticals	$34.53	$70.80	105.04%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
BOLT	Bolt Biotherapeutics	$0.54	$1.00	85.19%	Hold
ACHV	Achieve Life Sciences	$4.16	$4.75	14.18%	Buy

ACHV Forecast FAQ

Is Achieve Life Sciences a good buy?

Yes, according to 3 Wall Street analysts, Achieve Life Sciences (ACHV) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of ACHV's total ratings.

What is ACHV's price target?

Achieve Life Sciences (ACHV) average price target is $4.75 with a range of $4 to $5.5, implying a 28.73% from its last price of $3.69. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Achieve Life Sciences stock go up soon?

According to Wall Street analysts' prediction for ACHV stock, the company can go up by 28.73% (from the last price of $3.69 to the average price target of $4.75), up by 49.05% based on the highest stock price target, and up by 8.40% based on the lowest stock price target.

Can Achieve Life Sciences stock reach $6?

ACHV's average twelve months analyst stock price target of $4.75 does not support the claim that Achieve Life Sciences can reach $6 in the near future.

What are Achieve Life Sciences's analysts' financial forecasts?

Achieve Life Sciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-29.244M (high $-25.336M, low $-32.761M), average SG&A $0 (high $0, low $0), and average EPS is $-0.851 (high $-0.738, low $-0.954). ACHV's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-43.517M (high $-41.868M, low $-45.165M), average SG&A $0 (high $0, low $0), and average EPS is $-1.267 (high $-1.219, low $-1.315).

Did the ACHV's actual financial results beat the analysts' financial forecasts?

In terms of the last quarterly report (Mar 2016), Achieve Life Sciences's revenue was $2.94M, beating the average analysts' forecast of $2.86M by 2.88%. The company's EBITDA was $-3.651M, beating the average prediction of $-3.546M by 2.97%. Achieve Life Sciences's net income was $-2.982M, missing the average estimation of $-3.6M by -17.17%. The company's SG&A was $2.3M, beating the average forecast of $2.23M by 2.97%. Lastly, the company's EPS was $-220, beating the average prediction of $-12.46 by 1665.17%